<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641160</url>
  </required_header>
  <id_info>
    <org_study_id>MT-CL002</org_study_id>
    <nct_id>NCT00641160</nct_id>
  </id_info>
  <brief_title>Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metronome Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metronome Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of oral administration of vinorelbine
      once daily for at least 7 days. The study will be conducted in subjects with a
      non-hematologic malignancy for which there are no currently accepted therapies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse events, physical examinations, clinical laboratory assessments, and vital signs</measure>
    <time_frame>Assessed at each subject visit to the study center</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of orally administered vinorelbine</measure>
    <time_frame>Samples collected on Study Days 1, 2, and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis of blood markers of biological activity</measure>
    <time_frame>Blood samples collected at selected subject visits to the study center</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Nonhematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Dose Level #1 PO for at least 7 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Dose Level #2 PO for at least 7 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Dose Level #3 PO for at least 7 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  capable of understanding study requirements and able to provide Informed Consent

          -  diagnosed with a non-hematologic malignancy for which there are no currently accepted
             therapies

          -  life expectancy at least 3 months

          -  agreement to use medically acceptable contraception throughout the study

          -  willing and able to comply with the protocol requirements

        Exclusion Criteria:

          -  currently receiving systemic treatment for malignancy

          -  not yet recovered from the toxicity of prior therapies

          -  platelet count &lt; 100,000 cells/mm3 within 7 days prior to study entry

          -  ANC &lt; 1500 cells/mm3 within 7 days prior to study entry

          -  hemoglobin &lt; 8.5 g/dL within 7 days prior to study entry

          -  AST and/or ALT &gt; 2.5 X ULN within 7 days prior to study entry

          -  total bilirubin &gt; 1.5 X ULN within 7 days prior to study entry

          -  creatinine clearance &lt; 60 mL/min (Cockroft-Gault formula) within 7 days prior to study
             entry

          -  receipt of any investigational therapy within 3 weeks prior to study entry

          -  known history of HIV, HBV, and/or HCV infection

          -  clinically relevant active infection or serious co-morbid medical condition at study
             entry

          -  major surgery within 4 weeks prior to study entry

          -  other malignancy within 3 year prior to study entry

          -  pregnant or breast-feeding

          -  presence of a concomitant disease or condition which, in the opinion of the
             Investigator, could interfere with the conduct of the study or could put the subject
             at unacceptable risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Tidmarsh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Metronome Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Oncology PA; Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>George Tidmarsh, MD, PhD</name_title>
    <organization>Metronome Therapeutics</organization>
  </responsible_party>
  <keyword>vinorelbine</keyword>
  <keyword>metronomic dosing</keyword>
  <keyword>oral administration</keyword>
  <keyword>nonhematologic malignancies</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

